(PharmaNewsWire.Com, January 31, 2017 ) Neurofibromatoses Type I (Von Recklinghausen’s Disease) Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics industry report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy. Browse a Report Copy at: http://www.absolutereports.com/neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h2-2016-10512168 The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline Review, H2 2016: • Alexion Pharmaceuticals Inc • AstraZeneca Plc • Celldex Therapeutics Inc
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Neurofibromatoses Type I (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders)
Key Topics Covered: 1.Introduction 2.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Overview 3.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics Development 4.Pipeline Products for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview 5.Pipeline Products for Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Comparative Analysis 6.Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics under Development by Companies 7.Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics under Investigation by Universities/Institutes 8.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Products Glance 9.Late Stage Products 10.Clinical Stage Products 11.Early Stage Products 12.Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Products under Development by Companies 13.Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Products under Investigation by Universities/Institutes 14.Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development 15.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drug Profiles 16.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Dormant Projects 17.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Discontinued Products 18.Neurofibromatoses Type I (Von Recklinghausen’s Disease) Featured News & Press Releases And Continue… Sample PDF of Neurofibromatoses Type I (Von Recklinghausen’s Disease) Pipeline Review H2 2016 Research Study at: http://www.absolutereports.com/enquiry/request-sample/10512168
This research study help to: - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Ask Discount on Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics Companies Review H2 2016 Research Report at: http://www.absolutereports.com/enquiry/request-discount/10512168 About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – sales@absolutereports.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
